New hope for Hard-to-Treat blood cancers: experimental combo targets relapsed AML and MDS
NCT ID NCT05986240
First seen Nov 11, 2025 · Last updated May 16, 2026 · Updated 22 times
Summary
This early-phase study tests a new drug called danvatirsen, first alone and then combined with venetoclax, in 38 adults whose acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) have returned or not responded to standard treatments. The goal is to see if the drug is safe and can shrink or control the cancer. Participants must be 18 or older and have no other approved treatment options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M.D. Anderson Cancer Center, Department of Leukemia
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Montefiore Medical Center
RECRUITINGThe Bronx, New York, 10467, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.